Flyer

International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 51
  • Journal CiteScore: 46.50
  • Journal Impact Factor: 26.99
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • J-Gate
  • SHERPA ROMEO
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

Abstract

In-Vitro and In-Vivo evaluation of Transdermal prolonged release proniosomal gel formulations of Propranolol HCL

Jeevana Jyothi B, Guru Lakshmi. G

Propranolol HCl, an antihypertensive drug was formulated as transdermal prolonged release proniosomal gel due its drawback of short life when given through oral route. Nine formulations of proniosomes were prepared using different polymers viz. Maltodextrin, span 40, span 60 and cholesterol by slurry, slow stirring method. All were in turn prepared as proniosomal gels by using carbapol 940 by simple stirring. Gels were evaluated for entrapment efficiency, In-vitro skin permeation studies, scanning electron microscopy (SEM) analysis, vesicle size analysis, drug excipient interaction studies. Different release models like zero order, first order, Higuchi, Korsmeyer-peppas etc were applied to in-vitro drug release data in order to evaluate the drug release mechanisms and kinetics. Among all proniosomal transdermal gel formulation, F5 produced from pronisomal powder containing 10mg of Propranolol HCl , 100mg of cholesterol, 100mg of maltodextin, Span 40 and Span 60 each of 250mg exhibited ideal diffusion characteristics of 20.25% release at 2nd hr followed by controlled release for 12 hrs with 80.5% release at 12th hr. In-vivo evaluation of pharmacokinetic evaluation exhibited remarkable enhancement of elimination half life up to 13.08 hrs.